Adolescents and young adults on TMP-SMX have a higher 30-day risk of acute respiratory failure than those on amoxicillin or cephalosporins. The study supports the FDA's warning about TMP-SMX, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback